story of the week
Evolocumab for Cardiovascular Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Inclisiran Reduces LDL Cholesterol in Patients at High Cardiovascular Risk
- Lipid-Reduction Variability and Antidrug-Antibody Formation With Bococizumab
- Bococizumab Reduces Cardiovascular Events in High-Risk Patients
- 2017 Top Stories in Cardiology: Novel Therapies Plumb the Depths of Cholesterol and Can Improve Cardiovascular Outcomes
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease
N. Engl. J. Med 2017 Mar 17;[EPub Ahead of Print], MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, SA Murphy, JF Kuder, H Wang, T Liu, SM Wasserman, PS Sever, TR PedersenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.